Search company, investor...

Predict your next investment

QHP Capital company logo
Private Equity
FINANCE | Investment Firms & Funds
qhpcapital.com

Investments

41

Portfolio Exits

15

Funds

11

Partners & Customers

4

Service Providers

1

About QHP Capital

QHP Capital manages private equity and other investments in the global biopharmaceutical sector, where its principal focus is investing in late-stage clinical assets and commercial-phase biopharmaceutical products. It contracts with global biopharmaceutical corporations to invest side-by-side in strategic development and commercialization programs. The company was formerly known as NovaQuest Capital Management and changed its name to QHP Capital in October 2022. The company was founded in 2010 and is based in Raleigh, North Carolina.

Headquarters Location

4208 Six Forks Road Suite 920

Raleigh, North Carolina, 27609,

United States

919-261-5250

Want to inform investors similar to QHP Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest QHP Capital News

09:00 ET Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Approval of Oteseconazole Ca...

Aug 21, 2023

News provided by Share this article in treating women with severe VVC -   Oteseconazole Capsules were found to be safe and more effective than fluconazole -   China commercial launch of Oteseconazole Capsules expected in late 2023 DURHAM, N.C., Aug. 21, 2023 /PRNewswire/ -- Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") received approval in June from the National Medical Products Administration for Oteseconazole Capsules, an azole antifungal, indicated for the treatment of severe vulvovaginal candidiasis (VVC). Oteseconazole Capsules is contraindicated for females of reproductive potential, pregnant and lactating women, patients with known hypersensitivity to active ingredients, excipients and azoles. The approval of Oteseconazole Capsules for the treatment of severe VVC in China is an important milestone under Mycovia's exclusive agreement with Hengrui to develop and commercialize oteseconazole in China, including Mainland China, Hong Kong, Macau and Taiwan, for the treatment or prevention of a range of fungal conditions. The approval of Oteseconazole Capsules was based on a Phase 3 study with 322 patients at 27 sites. The primary study endpoint was the proportion of subjects with therapeutic cure (defined as the absence of symptoms and signs of VVC with negative fungal culture candidiasis) at Day 28. In a randomized Phase 3 clinical study to evaluate the efficacy and safety of a two-day dosing regimen of SHR8008 (oteseconazole capsules) versus the current standard-of-care fluconazole in patients with severe VVC, therapeutic cure at Day 28 was significantly higher in the SHR8008 group than in the fluconazole group (66.88% vs 45.91%), p = 0.0002. Mycological cure at Day 28 was higher in the SHR8008 group than in the fluconazole group (82.50% vs 59.12%), p < 0.0001. Therapeutic cure and mycological cure at Day 14 were also statistically superior for subjects receiving SHR8008 compared to those receiving fluconazole. Reported adverse events were similar between treatment groups. "We celebrate and congratulate our partner, Hengrui, on receiving its approval for Oteseconazole Capsules for the treatment of severe VVC," said Patrick Jordan, CEO of Mycovia and Managing Partner at NovaQuest Capital Management. "The disease burden in China is significant and the approval of Oteseconazole Capsules gives another treatment option for those women suffering with VVC." Vulvovaginal candidiasis is an exceedingly common mucosal infection usually caused by Candida albicans but can occasionally be caused by other Candida species or yeasts. Typical symptoms include vulvovaginal itching, irritation, burning, soreness, fissuring, redness, vaginal discharge, and dyspareunia. Approximately 70% to 75% of women in all strata of the society will experience at least one episode during their lifetime. Oteseconazole is designed to selectively inhibit fungal CYP51, which is required for fungal cell wall integrity, and this interaction is also toxic to fungi, resulting in the inhibition of fungal growth. Due to its chemical structure, oteseconazole has a lower affinity for human CYP enzymes as compared to fungal CYP enzymes. In April 2022, the U.S. Food and Drug Administration (FDA) approved VIVJOA® (oteseconazole) Capsules, as the first medication for Recurrent Vulvovaginal Candidiasis (chronic yeast infection). About Recurrent Vulvovaginal Candidiasis RVVC is a debilitating, chronic infectious condition that affects 138 million women worldwide each year. RVVC, also known as chronic yeast infection, is a distinct condition from vulvovaginal candidiasis (VVC) and defined by the Centers for Disease Control and Prevention as three or more symptomatic acute episodes of yeast infection in 12 months. Primary symptoms include vaginal itching, burning, irritation and inflammation. Some women may experience abnormal vaginal discharge and painful sexual intercourse or urination, causing variable but often severe discomfort and pain. About VIVJOA® VIVJOA® (oteseconazole) is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. VIVJOA is the first FDA-approved medication that provides sustained efficacy demonstrated by significant long-term reduction of RVVC recurrence through 50 weeks versus comparators. Oteseconazole is designed to inhibit fungal CYP51, which is required for fungal cell wall integrity, and this selective interaction is also toxic to fungi, resulting in the inhibition of fungal growth. Due to its chemical structure, oteseconazole has a lower affinity for human CYP enzymes as compared to fungal CYP enzymes. The FDA approved VIVJOA based upon the positive results from three phase 3 clinical trials of oteseconazole – two global VIOLET studies and one U.S.-focused ultraVIOLET study, including 875 patients at 232 sites across 11 countries. Please click here  for full Prescribing Information. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS VIVJOA is contraindicated in females of reproductive potential. Females who are NOT of reproductive potential are defined as: persons who are biological females who are postmenopausal or have another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy). VIVJOA is contraindicated in pregnant and lactating women. VIVJOA is contraindicated in patients with known hypersensitivity to oteseconazole. WARNINGS AND PRECAUTIONS Based on animal studies, VIVJOA may cause fetal harm. The drug exposure window of approximately 690 days (based on 5 times the half-life of oteseconazole) precludes adequate mitigation of the embryo-fetal toxicity risks. Advise patients that VIVJOA is contraindicated in females of reproductive potential, and in pregnant and lactating women because of potential risks to a fetus or breastfed infant. ADVERSE REACTIONS The most frequently reported adverse reactions among VIVJOA-treated patients in clinical studies included headache (7.4%) and nausea (3.6%). DRUG INTERACTIONS VIVJOA is a Breast Cancer Resistance Protein (BCRP) inhibitor. Concomitant use of VIVJOA with BCRP substrates (e.g., rosuvastatin) may increase the exposure of BCRP substrates, which may increase the risk of adverse reactions associated with these drugs. To report SUSPECTED ADVERSE REACTIONS, contact Mycovia Pharmaceuticals, Inc. at 1-855-299-0637 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . About Mycovia Pharmaceuticals, Inc. Mycovia Pharmaceuticals, Inc. is an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies. VIVJOA® (oteseconazole) capsules, the first FDA-approved product for Mycovia, is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations to become the first FDA-approved therapy for RVVC. In 2019, Mycovia licensed oteseconazole to Jiangsu Hengrui Pharmaceuticals Co., Ltd., to develop and commercialize oteseconazole in China, including mainland China, Hong Kong, Macau and Taiwan. Mycovia also recognizes a tremendous potential for its oral fungal inhibitors and a growing need to treat a range of multi-drug resistant fungal pathogens. For more information, please visit www.mycovia.com . About Jiangsu Hengrui Pharmaceuticals Co., Ltd. Hengrui Pharma is a leading global pharmaceutical company headquartered in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Innovation is the core development strategy. Hengrui Pharma ranked 21st among the top 1,000 global pharmaceutical companies in 2021.1 Hengrui Pharma has been on the Pharma Exec's annual listing of the top global pharmaceutical companies for the fourth consecutive year, rising from the 47th in 2019 to the 32nd in 2021.2 1.   https://torreya.com/publications/pharma-1000-report-torreya-2021-11-08.pdf ; page 49 and 56. 2.   https://www.pharmexec.com/view/2022-pharm-exec-top-50-companies ; page 24 About NovaQuest Capital Management Founded by a team of accomplished industry professionals in 2010, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a Product Finance solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate significantly higher than the industry average. NovaQuest is actively evaluating and investing into global opportunities with financing needs that range from $30-100 million. For more information, please visit www.novaquest.com . SOURCE Mycovia Pharmaceuticals, Inc.

QHP Capital Investments

41 Investments

QHP Capital has made 41 investments. Their latest investment was in COPILOT as part of their Private Equity on January 1, 2023.

CBI Logo

QHP Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/10/2023

Private Equity

COPILOT

Yes

1

5/25/2022

Series C

Targan

$35M

Yes

5

11/30/2021

Secondary Market

CovenantAH

Yes

2

6/8/2021

Revenue Finance

Subscribe to see more

$99M

Subscribe to see more

10

5/3/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/10/2023

5/25/2022

11/30/2021

6/8/2021

5/3/2021

Round

Private Equity

Series C

Secondary Market

Revenue Finance

Series A

Company

COPILOT

Targan

CovenantAH

Subscribe to see more

Subscribe to see more

Amount

$35M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

5

2

10

10

QHP Capital Portfolio Exits

15 Portfolio Exits

QHP Capital has 15 portfolio exits. Their latest portfolio exit was Aceragen (acquired by Idera Pharmaceuticals) on September 28, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/28/2022

Acquired

$99M

10

10/11/2021

Spinoff / Spinout

QHP Capital

$99M

1

10/1/2021

Reverse Merger

$99M

4

1/4/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

8/5/2020

Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/28/2022

10/11/2021

10/1/2021

1/4/2021

8/5/2020

Exit

Acquired

Spinoff / Spinout

Reverse Merger

Acquired

Merger

Companies

QHP Capital

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

10

1

4

10

10

QHP Capital Acquisitions

7 Acquisitions

QHP Capital acquired 7 companies. Their latest acquisition was AutoCruitment on October 27, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/27/2022

Seed / Angel

$99M

$0.02M

Acq - Fin

1

1/19/2021

Debt

Subscribe to see more

$99M

$99M

Subscribe to see more

10

11/2/2018

Subscribe to see more

$99M

Subscribe to see more

10

5/14/2018

Debt

Subscribe to see more

$99M

$99M

Subscribe to see more

10

3/26/2018

Debt

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

10/27/2022

1/19/2021

11/2/2018

5/14/2018

3/26/2018

Investment Stage

Seed / Angel

Debt

Debt

Debt

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$0.02M

$99M

$99M

$99M

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

QHP Capital Fund History

11 Fund Histories

QHP Capital has 11 funds, including NovaQuest Private Equity Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

5/12/2022

NovaQuest Private Equity Fund II

$500M

1

11/5/2019

NovaQuest Private Equity Fund I

Diversified Private Equity

Closed

$275M

6

6/24/2019

NovaQuest Pharma Opportunities Fund V

Diversified Private Equity

Open

$892.75M

5

3/8/2019

NQ PE Project Constellation

$99M

10

6/29/2018

NQ PE Project Kit LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

5/12/2022

11/5/2019

6/24/2019

3/8/2019

6/29/2018

Fund

NovaQuest Private Equity Fund II

NovaQuest Private Equity Fund I

NovaQuest Pharma Opportunities Fund V

NQ PE Project Constellation

NQ PE Project Kit LP

Fund Type

Diversified Private Equity

Diversified Private Equity

Subscribe to see more

Status

Closed

Open

Subscribe to see more

Amount

$500M

$275M

$892.75M

$99M

$99M

Sources

1

6

5

10

10

QHP Capital Partners & Customers

4 Partners and customers

QHP Capital has 4 strategic partners and customers. QHP Capital recently partnered with Hansa Biopharma on July 7, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

7/18/2022

Vendor

Sweden

Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform

Hansa Biopharma AB and NovaQuest Capital Management have also entered into a security agreement to provide NovaQuest Capital Management a customary security interest in and lien upon right , title and interest in certain of Hansa Biopharma AB 's assets and IP .

1

3/29/2022

Partner

Germany

Subscribe to see more

Subscribe to see more

10

3/29/2022

Partner

Germany

Subscribe to see more

Subscribe to see more

10

5/14/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

7/18/2022

3/29/2022

3/29/2022

5/14/2018

Type

Vendor

Partner

Partner

Partner

Business Partner

Country

Sweden

Germany

Germany

United States

News Snippet

Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform

Hansa Biopharma AB and NovaQuest Capital Management have also entered into a security agreement to provide NovaQuest Capital Management a customary security interest in and lien upon right , title and interest in certain of Hansa Biopharma AB 's assets and IP .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

QHP Capital Service Providers

1 Service Provider

QHP Capital has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Private Equity, and Acq - Fin

Counsel

General Counsel

Service Provider

Associated Rounds

Private Equity, and Acq - Fin

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

QHP Capital Team

4 Team Members

QHP Capital has 4 team members, including current Chief Financial Officer, Robert Hester.

Name

Work History

Title

Status

Robert Hester

Chief Financial Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Robert Hester

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Financial Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare QHP Capital to Competitors

Pagan Research Logo
Pagan Research

Pagan Research is an online B2B database and business intelligence website. It delivers quality data for the US, Asia, and EU regions' startups, recent fundings, exits, and more. The company was founded in 2016 and is based in Boston, Massachusetts.

E
ElexoPharm

ElexoPharm is a German biotech company, founded as a spin-off of the Department of Pharmaceutical and Medicinal Chemistry of Saarland University. ElexoPharm is focused on the preclinical discovery and optimization of drugs for human diseases, which are currently not or insufficiently treatable with existing drugs.

Sai Life Sciences Logo
Sai Life Sciences

Sai Life Sciences offers their clients a wide range of integrated drug discovery, development and formulation services, with core expertise founded in synthetic, medicinal and process chemistry and further augmented by a suite of preclinical support services including DMPK, toxicology and formulation that are continually expanding to meet clients' needs.

A
Ardent Health Services

Ardent Health Services, previously known as Behavioral Healthcare, invests in people, technology, facilities, and communities, producing high-quality care and extraordinary results. Ardent currently operates three health systems with a range of hospitals and employs multi-specialty physicians in multiple clinic locations across New Mexico, Oklahoma, and Texas. The company was founded in 1993 and is based in Nashville, Tennessee.

V
Veractect

Veratect offers services that aim to offer the early detection, 24/7 tracking and actionable alert generation of emerging threats (pandemics) worldwide. The company offers the Foreshadow and VeraSight. Per the company, Veratect provides timely and actionable information that supports informed decisions across a broad range of public and private institutions. By identifying emerging risks early, Veratect contends that actions can be taken that save human life, enable loss control, preserve business processes, safeguard supply chain operations and facilities, better manage financial reporting and insurance coverage, and mitigate potential class action lawsuits due to negligence in responding to threats in a timely manner.

Blaze Systems Logo
Blaze Systems

Blaze Systems is a provider of total LIMS software solutions for the laboratory marketplace.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.